157 related articles for article (PubMed ID: 16335914)
1. Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes.
Jäger D; Karbach J; Pauligk C; Seil I; Frei C; Chen YT; Old LJ; Knuth A; Jäger E
Cancer Immun; 2005 Dec; 5():11. PubMed ID: 16335914
[TBL] [Abstract][Full Text] [Related]
2. Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1.
Wang W; Epler J; Salazar LG; Riddell SR
Cancer Res; 2006 Jul; 66(13):6826-33. PubMed ID: 16818660
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
Jäger E; Chen YT; Drijfhout JW; Karbach J; Ringhoffer M; Jäger D; Arand M; Wada H; Noguchi Y; Stockert E; Old LJ; Knuth A
J Exp Med; 1998 Jan; 187(2):265-70. PubMed ID: 9432985
[TBL] [Abstract][Full Text] [Related]
4. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
[TBL] [Abstract][Full Text] [Related]
5. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma.
Rimoldi D; Rubio-Godoy V; Dutoit V; Lienard D; Salvi S; Guillaume P; Speiser D; Stockert E; Spagnoli G; Servis C; Cerottini JC; Lejeune F; Romero P; Valmori D
J Immunol; 2000 Dec; 165(12):7253-61. PubMed ID: 11120859
[TBL] [Abstract][Full Text] [Related]
6. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.
Jäger E; Nagata Y; Gnjatic S; Wada H; Stockert E; Karbach J; Dunbar PR; Lee SY; Jungbluth A; Jäger D; Arand M; Ritter G; Cerundolo V; Dupont B; Chen YT; Old LJ; Knuth A
Proc Natl Acad Sci U S A; 2000 Apr; 97(9):4760-5. PubMed ID: 10781081
[TBL] [Abstract][Full Text] [Related]
7. [Estimation of an NY-ESO-1 expressing HCC cell line by NY-ESO-1b specific CD8+T cells in vitro induced by HLA-A2 restricted NY-ESO-1b peptide].
Qiao H; Qian XP; Zhang HG; Tian C; Chen WF
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):565-8. PubMed ID: 16378102
[TBL] [Abstract][Full Text] [Related]
8. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
[TBL] [Abstract][Full Text] [Related]
9. Identification of NY-BR-1-specific CD4(+) T cell epitopes using HLA-transgenic mice.
Gardyan A; Osen W; Zörnig I; Podola L; Agarwal M; Aulmann S; Ruggiero E; Schmidt M; Halama N; Leuchs B; von Kalle C; Beckhove P; Schneeweiss A; Jäger D; Eichmüller SB
Int J Cancer; 2015 Jun; 136(11):2588-97. PubMed ID: 25387692
[TBL] [Abstract][Full Text] [Related]
10. A transplantable tumor model allowing investigation of NY-BR-1-specific T cell responses in HLA-DRB1*0401 transgenic mice.
Das K; Eisel D; Vormehr M; Müller-Decker K; Hommertgen A; Jäger D; Zörnig I; Feuerer M; Kopp-Schneider A; Osen W; Eichmüller SB
BMC Cancer; 2019 Sep; 19(1):914. PubMed ID: 31519152
[TBL] [Abstract][Full Text] [Related]
11. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.
Olson BM; Frye TP; Johnson LE; Fong L; Knutson KL; Disis ML; McNeel DG
Cancer Immunol Immunother; 2010 Jun; 59(6):943-53. PubMed ID: 20140431
[TBL] [Abstract][Full Text] [Related]
12. Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum.
Jäger D; Unkelbach M; Frei C; Bert F; Scanlan MJ; Jäger E; Old LJ; Chen YT; Knuth A
Cancer Immun; 2002 Jun; 2():5. PubMed ID: 12747750
[TBL] [Abstract][Full Text] [Related]
13. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
[TBL] [Abstract][Full Text] [Related]
14. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library.
Jäger D; Stockert E; Güre AO; Scanlan MJ; Karbach J; Jäger E; Knuth A; Old LJ; Chen YT
Cancer Res; 2001 Mar; 61(5):2055-61. PubMed ID: 11280766
[TBL] [Abstract][Full Text] [Related]
15. The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer.
Seil I; Frei C; Sültmann H; Knauer SK; Engels K; Jäger E; Zatloukal K; Pfreundschuh M; Knuth A; Tseng-Chen Y; Jungbluth AA; Stauber RH; Jäger D
Int J Cancer; 2007 Jun; 120(12):2635-42. PubMed ID: 17330232
[TBL] [Abstract][Full Text] [Related]
16. Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method.
Nakatsura T; Senju S; Ito M; Nishimura Y; Itoh K
Eur J Immunol; 2002 Mar; 32(3):826-36. PubMed ID: 11870627
[TBL] [Abstract][Full Text] [Related]
17. Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.
Wagner C; Neumann F; Kubuschok B; Regitz E; Mischo A; Stevanovic S; Friedrich M; Schmidt W; Rammensee HG; Pfreundschuh M
Cancer Immun; 2003 Dec; 3():18. PubMed ID: 14677925
[TBL] [Abstract][Full Text] [Related]
18. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
Maraskovsky E; Sjölander S; Drane DP; Schnurr M; Le TT; Mateo L; Luft T; Masterman KA; Tai TY; Chen Q; Green S; Sjölander A; Pearse MJ; Lemonnier FA; Chen W; Cebon J; Suhrbier A
Clin Cancer Res; 2004 Apr; 10(8):2879-90. PubMed ID: 15102697
[TBL] [Abstract][Full Text] [Related]
19. Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response.
Di Modugno F; Bronzi G; Scanlan MJ; Del Bello D; Cascioli S; Venturo I; Botti C; Nicotra MR; Mottolese M; Natali PG; Santoni A; Jager E; Nisticò P
Int J Cancer; 2004 May; 109(6):909-18. PubMed ID: 15027125
[TBL] [Abstract][Full Text] [Related]
20. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
